Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Poster Session Abstracts

Abstract P5-12-13: What goes through your mind when you think about your medication? Thoughts about endocrine medication and treatment adherence

AH Partridge, K Fasse, AL Stanton, A Jones, E Bright and KJ Petrie
AH Partridge
Dana-Farber Cancer Institute, Boston, MA; University of Auckland, Auckland, New Zealand; University of California, Los Angeles, Los Angeles, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
K Fasse
Dana-Farber Cancer Institute, Boston, MA; University of Auckland, Auckland, New Zealand; University of California, Los Angeles, Los Angeles, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
AL Stanton
Dana-Farber Cancer Institute, Boston, MA; University of Auckland, Auckland, New Zealand; University of California, Los Angeles, Los Angeles, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A Jones
Dana-Farber Cancer Institute, Boston, MA; University of Auckland, Auckland, New Zealand; University of California, Los Angeles, Los Angeles, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
E Bright
Dana-Farber Cancer Institute, Boston, MA; University of Auckland, Auckland, New Zealand; University of California, Los Angeles, Los Angeles, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KJ Petrie
Dana-Farber Cancer Institute, Boston, MA; University of Auckland, Auckland, New Zealand; University of California, Los Angeles, Los Angeles, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1538-7445.SABCS15-P5-12-13 Published February 2016
  • Article
  • Info & Metrics
Loading
Abstracts: Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 8-12, 2015; San Antonio, TX

Abstract

Hormonal therapy in women with breast cancer is an important part of long-term treatment, conferring significant survival benefits. However, a substantial proportion of women are non-adherent to endocrine therapy. Patients' beliefs about their illness and subsequent thoughts about whether the treatment is appropriate for their condition are important factors in treatment adherence. We sought to investigate the thoughts that breast cancer patients have about their endocrine medication and how these thoughts are related to adherence to treatment. Methods: Women with breast cancer were recruited from the Army of Women research registry. Women were asked what thoughts go through their mind when they think about the endocrine medication they were taking. Open-ended responses were coded reliably into 9 independent categories. Adherence to endocrine therapy, using an adapted version of the Morisky Medication Adherence Scale, as well as demographic and medical information was collected. Analysis of covariance (ANCOVA) was used to investigate the relation of treatment-related thoughts with adherence. Results: 1371 women were included in this analysis, mean age 56 years; 76.4% married, 57% currently working full or part-time. Mean years since breast cancer diagnosis was 5.1 years, and most women had early stage breast cancer (87%). With regard to endocrine therapy, 36.3% of participants were taking Arimidex (anastrazole), 29.6% Nolvadex (tamoxifen), 21.5% Femara (letrozole), and 12.5% Aromasin (exemestane). Of the 1371 participants, 1058 responses were able to be coded into 1 of the 9 categories. The most frequent category of thoughts reported was concern about side effects (19%) followed by the drug preventing cancer recurrence (18%), worry about future effects (13%), hope the drug is working (13%), dislike taking the drug (9%), time remaining on treatment (9%), grateful that drug exists (8%), and the drug is saving my life (6%). Treatment-related thoughts were related significantly to self-reported adherence to endocrine medication, F(8, 1013) = 5.97, p < .001, partial η2 = .05. Women who reported thinking that they don't like taking their medication were the least adherent to treatment (M = 7.01, 95%CI[6.60, 7.42]). This group reported significantly lower adherence than participants who reported feeling protected (M = 5.79, 95%CI[5.22, 6.37], p = .025), those who thought about their medication saving their lives (M = 5.88, 95%CI[5.40, 6.35], p = .014), preventing recurrence (M = 5.98, 95%CI[5.70, 6.26], p = .002), those who reported feeling grateful for treatment (M = 6.00, 95%CI[5.59, 6.42], p = .024), and those who thought about their hope that the treatment is working (M = 6.01, 95%CI[5.69, 6.34], p = .006). Women who were worried about the possible long-term effects of the treatment or were concerned about side effects were also significantly less adherent to treatment.

Conclusions: The thoughts that patients with breast cancer have about their medication are significantly related to adherence to endocrine therapy. This simple open-ended question may be useful to assess patients' experiences of their medication and identify cognitions that can be targeted in interventions to improve adherence.

Citation Format: Partridge AH, Fasse K, Stanton AL, Jones A, Bright E, Petrie KJ. What goes through your mind when you think about your medication? Thoughts about endocrine medication and treatment adherence. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P5-12-13.

Previous
Back to top
Cancer Research: 76 (4 Supplement)
February 2016
Volume 76, Issue 4 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract P5-12-13: What goes through your mind when you think about your medication? Thoughts about endocrine medication and treatment adherence
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract P5-12-13: What goes through your mind when you think about your medication? Thoughts about endocrine medication and treatment adherence
AH Partridge, K Fasse, AL Stanton, A Jones, E Bright and KJ Petrie
Cancer Res February 15 2016 (76) (4 Supplement) P5-12-13; DOI: 10.1158/1538-7445.SABCS15-P5-12-13

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract P5-12-13: What goes through your mind when you think about your medication? Thoughts about endocrine medication and treatment adherence
AH Partridge, K Fasse, AL Stanton, A Jones, E Bright and KJ Petrie
Cancer Res February 15 2016 (76) (4 Supplement) P5-12-13; DOI: 10.1158/1538-7445.SABCS15-P5-12-13
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Poster Session Abstracts

  • Abstract P6-14-05: Phase 2 study evaluating the efficacy and safety of eribulin mesylate administered biweekly for patients with human epidermal growth factor receptor 2-negative metastatic breast cancer
  • Abstract P6-08-07: Decline in compliance to breast cancer screening in France: Results of the 5th EDIFICE survey
  • Abstract P6-08-04: National trends in mastectomy for operable breast cancers treated with neoadjuvant chemotherapy
Show more 3

Treatment: Adjuvant Endocrine Therapy

  • Abstract P3-12-03: Impact of genetic polymorphisms on plasma levels of tamoxifen and its metabolites and toxicity: 6-months results of the adjuvant breast cancer longitudinal PHACS study (NCT01127295)
  • Abstract P3-12-11: Disparities in adjuvant hormone adherence in breast cancer patients within a universal healthcare model
  • Abstract P3-12-01: 0.005% estriol vaginal gel in hormone receptor-positive postmenopausal women with early stage breast cancer in treatment with aromatase inhibitors (AIs) in the adjuvant setting. A phase II prospective, randomized, double-blind placebo-controlled study - “the Blissafe study”
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement